Mark K. Louder

Active 1994–2025

91
Papers
22,991
Citations
73
h-index
85
i10-index

Citations

Citations per year for Mark K. Louder1993: 5 citations1994: 4 citations1995: 7 citations1996: 7 citations1997: 2 citations1998: 13 citations1999: 31 citations2000: 28 citations2001: 56 citations2002: 60 citations2003: 60 citations2004: 65 citations2005: 63 citations2006: 78 citations2007: 56 citations2008: 63 citations2009: 83 citations2010: 83 citations2011: 112 citations2012: 194 citations2013: 299 citations2014: 287 citations2015: 368 citations2016: 461 citations2017: 419 citations2018: 409 citations2019: 909 citations2020: 1,112 citations2021: 1,368 citations2022: 795 citations2023: 500 citations2024: 684 citations2025: 401 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,960 citing papers, 41.1% of this breakdownChina: 500 citing papers, 6.9% of this breakdownUnited Kingdom: 428 citing papers, 5.9% of this breakdownGermany: 267 citing papers, 3.7% of this breakdownNetherlands: 252 citing papers, 3.5% of this breakdownFrance: 243 citing papers, 3.4% of this breakdownCanada: 213 citing papers, 3% of this breakdownSouth Africa: 190 citing papers, 2.6% of this breakdownSwitzerland: 159 citing papers, 2.2% of this breakdownItaly: 138 citing papers, 1.9% of this breakdownIndia: 137 citing papers, 1.9% of this breakdownAustralia: 133 citing papers, 1.9% of this breakdown
0%41.1%Other 22%

Fields

  • Medicine44.7%
  • Immunology and Microbiology38.5%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Agricultural and Biological Sciences0.6%
  • Environmental Science0.3%
  • Engineering0.3%
  • Other1.8%

Topics

  • HIV Research and Treatment12.6%
  • SARS-CoV-2 and COVID-19 Research8.8%
  • Monoclonal and Polyclonal Antibodies Research5.7%
  • Immune Cell Function and Interaction5.5%
  • vaccines and immunoinformatics approaches3.8%
  • Immunotherapy and Immune Responses3.7%
  • Other59.9%

Coauthors

All papers

Open in search
  1. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emily Phung, Lauren A. Chang, Rebecca J. Loomis, Nedim Emil Altaras, Elisabeth Narayanan, Mihir Metkar, Vladimir Presnyak, Cuiping Liu, Mark K. Louder, Wei Shi, Kwanyee Leung, Eun Sung Yang, Ande West, Kendra L. Gully, Laura J. Stevens, Nianshuang Wang, Daniel Wrapp, Nicole A. Doria‐Rose, Guillaume Stewart-Jones, Hamilton Bennett, Gabriela Alvarado, Martha Nason, Tracy J. Ruckwardt, Jason S. McLellan, Mark R. Denison, James D. Chappell, Ian N. Moore, Kaitlyn M. Morabito, John R. Mascola, Ralph S. Baric, Andrea Carfı́, Barney S. Graham - Nature 2020 cited by 1,687

  2. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurent Pessaint, Alex Van Ry, Shanai Browne, Jack Greenhouse, Tammy Taylor, Amanda Strasbaugh, Tracey-Ann Campbell, Anthony Cook, Alan Dodson, Katelyn Steingrebe, Wei Shi, Yi Zhang, Olubukola M. Abiona, Lingshu Wang, Amarendra Pegu, Eun Sung Yang, Kwanyee Leung, Tongqing Zhou, I‐Ting Teng, Alicia T. Widge, Ingelise J. Gordon, Laura Novik, Rebecca A. Gillespie, Rebecca J. Loomis, Juan I. Moliva, Guillaume B. E. Stewart-Jones, Sunny Himansu, Wing‐Pui Kong, Martha Nason, Kaitlyn M. Morabito, Tracy J. Ruckwardt, Julie E. Ledgerwood, Martin R. Gaudinski, Peter D. Kwong, John R. Mascola, Andrea Carfı́, Mark G. Lewis, Ralph S. Baric, Adrian B. McDermott, Ian N. Moore, Nancy J. Sullivan, Mario Roederer, Robert A. Seder, Barney S. Graham - New England Journal of Medicine 2020 cited by 1,174

  3. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science 2010 cited by 1,802

  4. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael S. Seaman, Lawrence Shapiro, John R. Mascola, Peter D. Kwong, Mark Connors - Immunity 2016 cited by 395

  5. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cathy Masiello, Baishali Maskeri, Jenny McDowell, Casandra Montemayor, James C. Mullikin, Morgan Park, Nancy Riebow, Karen Schandler, Brian Schmidt, Christina Sison, Mal Stantripop, James Thomas, Pam Thomas, Meg Vemulapalli, Alice Young, James C. Mullikin, S. Gnanakaran, Peter Hraber, Kevin Wiehe, Garnett Kelsoe, Guang Yang, Shi-Mao Xia, David C. Montefiori, Robert E. Parks, Krissey E. Lloyd, Richard M. Scearce, Kelly A. Soderberg, Myron S. Cohen, Gift Kamanga, Mark K. Louder, Lillian Tran, Yue Chen, Fangping Cai, Sheri Chen, Stephanie Moquin, Xiulian Du, M. Gordon Joyce, Sanjay Srivatsan, Baoshan Zhang, Anqi Zheng, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette Korber, Peter D. Kwong, John R. Mascola, B F Haynes - Nature 2013 cited by 1,061

  6. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

    Authors: , , , , , , , , , , , , , , , , , , , - Nature 2012 cited by 852

  7. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yongping Yang, Zhenhai Zhang, NISC Comparative Sequencing, James C. Mullikin, James Μ. Binley, Rogier W. Sanders, Ian A. Wilson, John P. Moore, Andrew C. Ward, George Georgiou, Carolyn Williamson, Salim S. Abdool Karim, Lynn Morris, Peter D. Kwong, Lawrence Shapiro, John R. Mascola - Nature 2014 cited by 756

  8. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan Stuckey, Paul V. Thomas, Tishina Tittley, Constance Williams, Baoshan Zhang, Hong Zhao, Zhou Zhou, Bruce R. Donald, Lawrence K. Lee, Susan Zolla‐Pazner, Ulrich Baxa, Arne Schön, Ernesto Freire, Lawrence Shapiro, Kelly K. Lee, James Arthos, James B. Munro, Scott C. Blanchard, Walther Mothes, James Μ. Binley, Adrian B. McDermott, John R. Mascola, Peter D. Kwong - Nature Structural & Molecular Biology 2015 cited by 368

  9. Structure and immune recognition of trimeric pre-fusion HIV-1 Env

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature, Nat. 2014 cited by 779

  10. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yen‐Ting Lai, Thomas Lemmin, Krisha McKee, Tiffany Y. Ohr, Li Ou, Dongjun Peng, Ariana P. Rowshan, Zizhang Sheng, John-Paul Todd, Yaroslav Tsybovsky, Elise G. Viox, Yiran Wang, Hui Wei, Yongping Yang, Amy F. Zhou, Rui Chen, Lu Yang, Diana G. Scorpio, Adrian B. McDermott, Lawrence Shapiro, Bridget Carragher, Clinton S. Potter, John R. Mascola, Peter D. Kwong - Nature Medicine 2018 cited by 310

  11. Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lawrence Shapiro, Gary J. Nabel, John R. Mascola, Peter D. Kwong - Immunity 2013 cited by 387

  12. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hung‐Pin Peng, An‐Suei Yang, James C. Mullikin, Matthew D. Gray, Leonidas Stamatatos, Dennis R. Burton, Wayne C. Koff, Myron S. Cohen, Barton F. Haynes, Joseph P. Casazza, Mark Connors, Davide Corti, Antonio Lanzavecchia, Quentin J. Sattentau, Robin A. Weiss, Anthony P. West, Pamela J. Björkman, Johannes F. Scheid, Michel C. Nussenzweig, Lawrence Shapiro, John R. Mascola, Peter D. Kwong - Cell 2015 cited by 340

  13. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lynn Morris, John R. Mascola - Journal of Virology 2015 cited by 261

  14. Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David C. Montefiori, Ashley M. Trama, Hua‐Xin Liao, Thomas B. Kepler, M. Anthony Moody, Feng Gao, Samuel J. Danishefsky, John R. Mascola, George M. Shaw, Beatrice H. Hahn, Stephen C. Harrison, Bette Korber, Barton F. Haynes - Science Translational Medicine 2017 cited by 290

  15. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel E. Sam, Barton F. Haynes, Dennis R. Burton, Wayne C. Koff, Laura M. Walker, Sanjay Phogat, Richard T. Wyatt, Jared Orwenyo, Lai‐Xi Wang, James Arthos, Carole A. Bewley, John R. Mascola, Gary J. Nabel, William R. Schief, Andrew B. Ward, Ian A. Wilson, Peter D. Kwong - Nature 2011 cited by 853

  16. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Connors, Andrew B. Ward, Peter D. Kwong, John R. Mascola - Science 2016 cited by 377

  17. Human skin Langerhans cells are targets of dengue virus infection

    Authors: , , , , , , , , , , , , , , , , - Nature Medicine 2000 cited by 671

  18. Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James C. Mullikin, Lawrence Shapiro, Richard A. Koup, Barney S. Graham, Martha Nason, Mark Connors, Barton F. Haynes, Srinivas S. Rao, Mario Roederer, Peter D. Kwong, John R. Mascola, Gary J. Nabel - Journal of Virology 2014 cited by 291

  19. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brenna J. Hill, Rui Kong, Cinque Soto, James C. Mullikin, Daniel C. Douek, David C. Montefiori, Michael A. Moody, George M. Shaw, Beatrice H. Hahn, Garnett Kelsoe, Peter Hraber, Bette Korber, Scott D. Boyd, Andrew Fire, Thomas B. Kepler, Lawrence Shapiro, Andrew B. Ward, John R. Mascola, Hua‐Xin Liao, Peter D. Kwong, Barton F. Haynes - Cell 2016 cited by 341

  20. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mario Roederer, Mark Connors, Richard A. Koup, Peter D. Kwong, Zhiyong Yang, John R. Mascola, Gary J. Nabel - Science 2017 cited by 271

  21. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , - PLoS Pathogens 2016 cited by 200

  22. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James C. Mullikin, Gary J. Nabel, Mario Roederer, Lawrence Shapiro, Peter D. Kwong, John R. Mascola - Science 2011 cited by 820

  23. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chen‐Hsiang Shen, Yaroslav Tsybovsky, Yongping Yang, Peng Zhao, Barton F. Haynes, Leonidas Stamatatos, Michael Tiemeyer, Lance Wells, Diana G. Scorpio, Lawrence Shapiro, Adrian B. McDermott, John R. Mascola, Peter D. Kwong - Cell Reports 2017 cited by 196

  24. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2019 cited by 141